University of Tennessee Medical Center Selects Health Robotics' i.v.STATION Robot and i.v.SOFT
BOZEN, Sud-Tirol, Italy, December 17, 2012 /PRNewswire/ --
Health Robotics today announced that the University of Tennessee Medical Center in Knoxville [UTMC] has joined the growing number of American hospitals replacing their reliance on sterile compounding outsourcing with i.v.STATION. UTMC, a member of the Premier healthcare alliance, serves as a tertiary referral center for Eastern Tennessee, Southeast Kentucky and Western North Carolina. UTMC was the region's first Certified Primary Stroke Center and East Tennessee's first dedicated Heart Hospital, serving as the area's only Level I Trauma Center.
Kim Mason, Director of Pharmacy at University of Tennessee Medical Center stated: "the medical center has long sought after ways in which to improve quality, decrease labor expenses, reduce medications costs, increase sterile compounding throughput, and diminish reliance on expensive outsourced IV doses. Our Pharmacy Team conducted due diligence on the available IV Automation technologies including a site visit to Brigham & Women's Hospital, reaching the conclusion that the financial and quality benefits of Health Robotics' solutions were superior. UTMC plans to quickly go live on i.v.STATION and 5 i.v.SOFT Assist units during the first quarter of 2013."
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "After the disruption caused by the NECC and Ameridose closures following the FDA's inspections, Health Robotics quickly delivered i.v.STATION to UTMC within 2 weeks of purchase order in order to minimize the impact of IV medication supplies due to the above mentioned closings. i.v.STATION is quickly installed without disrupting existing sterile compounding operations, without requiring additional space in the pharmacy, and without costly construction expenses."
In the first quarter of 2012, Health Robotics was awarded a 3-year exclusive (sole- source) group purchasing agreement by Premier, a provider-owned healthcare alliance of 2,700 hospitals and 90,000 other sites. The agreement makes Health Robotics' i.v.STATION and i.v.STATION ONCO available to Premier members at specially negotiated pricing and terms. UT Medical Center is thus leading the American hospital pharmacy industry by engaging Health Robotics' assistance to improve quality, decrease labor and medication expenses, and reduce reliance on sterile compounding outsourcing, through the installation of i.v.STATION.
About Health Robotics:
Founded in 2006 and now reaching well over 80% global market share, Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with robotics-based technology and fully-integrated clinical software automation solutions. Health Robotics' second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
For additional information, please contact:
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Journal of Oncology Practice, November 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. mAbs January 2013, Volume 5, Issue 1.
SOURCE Health Robotics